Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Novartis
Queensland Health
UBS
Farmers Insurance
McKesson
Boehringer Ingelheim
Cipla
Healthtrust

Generated: October 17, 2017

DrugPatentWatch Database Preview

Tavaborole - Generic Drug Details

« Back to Dashboard

What are the generic sources for tavaborole and what is the scope of tavaborole patent protection?

Tavaborole
is the generic ingredient in one branded drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tavaborole has sixty-eight patent family members in twenty countries.

There are two drug master file entries for tavaborole. One supplier is listed for this compound.

Summary for Generic Name: tavaborole

US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list36
Patent Applications: see list68
Drug Prices:see low prices
DailyMed Link:tavaborole at DailyMed

Pharmacology for Ingredient: tavaborole

Ingredient-typeBoron Compounds
Drug ClassOxaborole Antifungal
Mechanism of ActionProtein Synthesis Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tavaborole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,722,917Boron-containing small molecules► Subscribe
7,767,657Boron-containing small molecules► Subscribe
8,115,026Boron-containing small molecules► Subscribe
8,440,642Boron-containing small molecules► Subscribe
8,889,656Boron-containing small molecules► Subscribe
8,039,451Boron-containing small molecules► Subscribe
9,353,133Boron-containing small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tavaborole

Country Document Number Estimated Expiration
South Korea20080110984► Subscribe
Mexico335993► Subscribe
China102532180► Subscribe
Israel207156► Subscribe
Russian Federation2008131324► Subscribe
Russian Federation2010133524► Subscribe
Japan2017105826► Subscribe
South Korea20130100019► Subscribe
South Korea20100105869► Subscribe
Cyprus1116454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cerilliant
Queensland Health
Argus Health
Medtronic
Harvard Business School
Healthtrust
Cantor Fitzgerald
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot